247 related articles for article (PubMed ID: 33789884)
21. Update to living WHO guideline on drugs for covid-19.
BMJ; 2021 Jul; 374():n1703. PubMed ID: 34230027
[No Abstract] [Full Text] [Related]
22. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
Kory P; Meduri GU; Varon J; Iglesias J; Marik PE
Am J Ther; 2021 Apr; 28(3):e299-e318. PubMed ID: 34375047
[TBL] [Abstract][Full Text] [Related]
23. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA; Wagstaff KM
Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233
[TBL] [Abstract][Full Text] [Related]
24. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
25. An EUA for bamlanivimab and etesevimab for COVID-19.
Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
[No Abstract] [Full Text] [Related]
26. Update to living systematic review on drug treatments for covid-19.
BMJ; 2020 Dec; 371():m4852. PubMed ID: 33334735
[No Abstract] [Full Text] [Related]
27. COVID-19 medical management including World Health Organization (WHO) suggested management strategies.
McFee DRB
Dis Mon; 2020 Sep; 66(9):101068. PubMed ID: 32907701
[No Abstract] [Full Text] [Related]
28. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
Martinez MA
Front Immunol; 2021; 12():635371. PubMed ID: 33777024
[No Abstract] [Full Text] [Related]
29. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
[TBL] [Abstract][Full Text] [Related]
30. New SARS-CoV-2 Variants Challenge Vaccines Protection.
Soriano V; Fernández-Montero JV
AIDS Rev; 2021 Feb; 23(1):57-58. PubMed ID: 33750742
[No Abstract] [Full Text] [Related]
31. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
Bhattacharyya P; Das S; Aich S; Sarkar J
Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
Fricke-Galindo I; Falfán-Valencia R
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807592
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 in Still's disease.
de Carvalho JF
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12627-12629. PubMed ID: 33378008
[No Abstract] [Full Text] [Related]
34. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
35. Familiar Dermatologic Drugs as Therapies for COVID-19.
Ortega-Peña M; González-Cuevas R
Actas Dermosifiliogr (Engl Ed); 2021 Feb; 112(2):118-126. PubMed ID: 33045209
[TBL] [Abstract][Full Text] [Related]
36. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.
Zarkesh K; Entezar-Almahdi E; Ghasemiyeh P; Akbarian M; Bahmani M; Roudaki S; Fazlinejad R; Mohammadi-Samani S; Firouzabadi N; Hosseini M; Farjadian F
Future Microbiol; 2021 Dec; 16():1415-1451. PubMed ID: 34812049
[TBL] [Abstract][Full Text] [Related]
37. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
38. Caution should be exercised when assessing ivermectin for the treatment of COVID-19 in systematic reviews.
Deng J; Zhou F; Heybati K; Kavanagh K
Rev Med Virol; 2022 Sep; 32(5):e2317. PubMed ID: 34888992
[No Abstract] [Full Text] [Related]
39. Update to living WHO guideline on drugs for covid-19.
BMJ; 2022 Sep; 378():o2224. PubMed ID: 36109041
[No Abstract] [Full Text] [Related]
40. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
